Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camlipixant DDI with Rifampin and Rabeprazole
NCT05899829Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of camlipixant in refractory chronic cough (RCC) and unexplained chronic cough (2 arms), sponsored by GSK. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity at Day 11, Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration at Day 11 and 1 more. Started Jun 2023; status: completed.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)unexplained chronic cough
Beyond the preview
Go deeper on NCT05899829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899829.